INTRODUCTION
============

World--wide seroepidemiological analyses of Kaposi\'s sarcoma associated herpesvirus (KSHV) have associated this virus with KS. Analyses of tissue biopsies by polymerase chain reaction (PCR) have identified KSHV in KS: including HIV/AIDS associated, classic (Mediterranean) and endemic (African). However, little is known about childhood endemic KS, childhood endemic KS (Sub--Saharan African regions). Childhood endemic KS can be rapid and aggressive, often presenting as lymphadenopathy, having disseminated forms. Childhood endemic KS has expanded since the HIV/ AIDS epidemic and extends to half of childhood cancers in some African countries, while practically absent in Europe or USA \[[@b32]\]. Is this a different strain or one now spread by HIV/AIDS as an emergent childhood disease? What are the implications for vaccine development for control? Here this is examined via analyses of genotypes in blood--borne infant infections in Zambia, a childhood endemic KS endemic region.

The highest childhood KSHV seroprevalence are in several African countries including Nigeria (20%), Uganda (21%), Zambia (47%), Egypt (44%), Tanzania (58%), and Cameroon (32%); increasing with age, for example, in adults the seroprevalence is higher in Tanzania (89%) and Cameroon (62%), as reviewed \[[@b32]; [@b23]\]. In contrast, childhood infection is rarely detected in USA and Europe (3%) \[[@b17]\]. Childhood infection in Africa can give rise to childhood endemic KS, but its not know whether these strains are different from adult infections, since frequent childhood infections are only observed where there is evidence for mother to child or close siblings transmission \[[@b32]; [@b23]\]. KSHV seroprevalence in African children is different fromthe relatedgammaherpesvirus,Epstein--Barr virus (EBV). By age three, 100% of children are EBV seropositive in Nigeria, and 79% of their blood DNA positive in Uganda, compared to KSHV where in these populations 20% were seropositive and 10% DNA positive in the respective studies \[[@b17]; [@b24]\]. Thus, KSHV childhood transmission is more restricted than EBV. Further, it increases with age, different from EBV. Thus, could distinct KSHV genotypes infect children compared to adults, as for Herpes simplex virus (HSV), where HSV--1 primarily infects children via saliva, while HSV--2 sexually transmitted in adults?

Previous analyses of KSHV genetic diversity by PCR on DNA extracted from adult KS biopsies followed by nucleotide sequencing, show hypervariable genes at either ends of the genome. These include K1 at the left hand end (genotypes A---F) and, K12 and K14.1/K15 (genotypes B, P, M, N, O) at the right \[[@b6]; [@b29]; [@b38]; [@b12]\]. In adult African endemic KS, two main K1 genotypes were identified A5 and B, with only a minority of the Eurasian C genotypes. While at the right hand end of the genome, there are B genotypes in K12; while there are P or M alleles for K14.1/K15, with P forms predominating in Eastern and Central Africa \[[@b29]; [@b16]; [@b12]\]. In contrast, in childhood endemic KS the K1--A5 genotype had been identified suggesting specific strains may infect the children (Zambia, 15 cases) \[;[@b13]\].

These diversity studies were on adult KS biopsies which have relatively high copy numbers, thus amenable to analyses. Less is known about virus genotypes infecting general populations. In adults, studies on PBMC DNA have detected K1--B and A5 genotypes in Gambia and Uganda, with similar results for adults from isolated Botswana tribes, where further variation was demonstrated \[[@b6]; [@b25]; [@b35]\]. In infants, however, studies of blood DNA from early infections have only been characterized in Zambia, where previous related studies identified K1--A5 after screening conserved genes (five cases), similar to the childhood endemic KS genotype identified in this population \[[@b13]\]. In order to test whether there are restricted genotypes in infant infections in childhood endemic KS endemic regions, a further study was undertaken analyzing blood DNA from a larger group of 200 infant patients, using multiple markers for sites of variation from both ends of the genome. Both HIV positive and negative hospitalized infants were studied in this childhood KS endemic region.

MATERIALS AND METHODS
=====================

Patients
--------

Peripheral blood samples were sequentially collected from 200 children, 6 months to 3 years, with non--specific febrile illness during 2003, admitted to Paediatrics Outpatients, University Teaching Hospital, Lusaka, Zambia. Fever (\>38°C) was an inclusion criteria, a consistent symptom from the few studies on primary KSHV childhood infection \[[@b13]; [@b1]\] childhood endemic KS had not been diagnosed in this cohort. Fever arising from malaria and bacterial pneumonia were excluded and no other diagnosable cause was reported. Samples were from spent blood after routine diagnostic tests were performed. Protocols were reviewed and approved by ethical committees at the University Teaching Hospital, Zambia and London School of Hygiene & Tropical Medicine, UK.

PCR
---

DNA was extracted from 200 µl whole blood (Qiagen, Crawley, UK) and resuspended in 50 µl nuclease--free H~2~O (Sigma, Gillingham, UK). PCR was carried in 20 µl reactions using 1 µl DNA with PCR master mix (Promega, Southampton, UK) and pfu polymerase with plus primers for human prolactin gene, KSHV K12 (646 bp, LGH2076/2075 and 407 bp, nested T07IF/ IR), K14.1/K15 (P,362 bp, and M,450 bpLGH2079, LGH2033, and LGH2506), HIV (BUP/UP/nested BU3) or HCMV (gN, gB1, and gB2, 150 bp) as described \[[@b13]; [@b27]; [@b29]; [@b19]; [@b35]; [@b18]\]; plus K1 vri designed to detect all genotypes: K1vri1 5′TGTCTGCAGTCTGGCGGTTTG 3′; K1vri2 5′ACACAAGGTTTGTAAGACAGG3′ and the conserved K4 gene as control: K41 5′ TGTGGATCCAACATGGGTATCGTT 3′; K42 5′ TTTGGATCCGAGTTGAGCTGTTTAC 3′. A strict three lab policy for PCR (DNA--free lab reagent addition, DNA lab for DNA addition, PCR lab for amplifications) was used against contamination and none detected; water negative controls for every 5--10 reactions, were negative. KSHV sequences collected had unique signatures.

Nucleotide Sequencing and Analysis
----------------------------------

The amplified PCR products were purified (Qiagen MinElute), followed by nucleotide sequencing using BigDye v3.1 (ABI) and ABI 3730 analyzer as described \[[@b19]\]. Sequence analyses used Chromas with Genbank comparisons using Blast and multiple alignments with ClustalW \[[@b5]\]. Phylogenetic trees were constructed using Phylip programs, with Blosum62 distance matrix, a topological tree algorithm and 100 bootstrap analyses \[[@b4]; [@b9]\]. Sequence submitted to EBI/Genbank.

RESULTS
=======

Detection of KSHV
-----------------

DNA was extracted from peripheral whole blood samples from the cohort of 200 febrile infants, hospitalized in Lusaka, Zambia. These were then analyzed by PCR and sequencing using primers specific for KSHV as well as human DNA control (Prolactin). All KSHV sequences collected had unique signatures and there was no evidence for PCR contamination. Moreover, many sequences subsequently derived had not been previously identified in the laboratory. One hundred and forty--one samples were included in the analyses which showed consistent results, and a positive human prolactin gene control.

PCR detection of HIV and KSHV was also compared with human cytomegalovirus (HCMV), another herpesvirus related to morbidity and mortality in these HIV positive children. The results showed HIV, KSHV, and HCMV detected in 39%, 22%, and 11% infants, respectively ([Table I](#tbl1){ref-type="table"}). KSHV and HCMV coinfections were rare (3/14 HCMV positive). Although co--infections with HIV were more frequently identified with KSHV than with HCMV (65% vs. 47%) supporting the expansion of this infection with HIV/AIDS consistent with studies in adults.

###### 

KSHV Genotypes in Hospitalized Febrile Infants (6--34 months) in Zambia

  Patient[a](#tf1-1){ref-type="table-fn"}   HIV   HCMV   KSHV   K1     K12   K14.1/15   Age     Symptoms
  ----------------------------------------- ----- ------ ------ ------ ----- ---------- ------- ------------------
  K2                                        \+    −      \+     A5     B1    P          6 mo    URTI
  K3                                        −     −      \+     A5     B1    P          8 mo    URTI
  K4                                        \+    −      \+     A5     B2    P          19 mo   URTI, Rash
  K33                                       −     \+     −      ---    ---   ---        6 mo    URTI
  K35                                       \+    −      \+     un     B1    P          11 mo   URTI, Diarrhoea
  K37                                       \+    −      \+     un     B2    P          15 mo   Fever
  K42                                       −     −      \+     un     B2    P          11 mo   Fever
  K46                                       \+    −      \+     B      B1    un         7 mo    Fever, Rhinitis
  K50                                       \+    −      \+     A2     B2    P          10 mo   URTI
  K54                                       \+    \+     \+     A2     B1    P          24 mo   Fever
  K55                                       \+    −      \+     un     B1    P          29 mo   Fever
  K57                                       \+    \+     −      ---    ---   ---        17 mo   Fever, Diarrhoea
  K58                                       \+    −      \+     A2     B1    P          3 yr    Fever
  K60                                       −     \+     −      ---    ---   ---        14 mo   Fever
  K61                                       \+    \+     −      ---    ---   ---        14 mo   Fever, Rash
  K73                                       \+    −      \+     A2     B2    P          13 mo   URTI
  K74                                       \+    −      \+     A5     B2    P          11 mo   Fever
  K75                                       \+    −      \+     un     B2    un         12 mo   Fever
  K78                                       −     −      \+     un     B1    P          15 mo   URTI
  K79                                       \+    −      \+     B      B1    P          19 mo   Fever
  K86                                       \+    \+     −      ---    ---   ---        6 mo    Fever
  K91                                       \+    −      \+     un     B1    P          10 mo   URTI, Diarrhoea
  K93                                       \+    \+     \+     un     B2    un         22 mo   Fever, Diarrhoea
  K111                                      −     −      \+     ABCD   B1    un         9 mo    Fever
  K113                                      −     −      \+     B      un    un         11 mo   Fever
  K117                                      \+    −      \+     B      B1    P          16 mo   URTI
  K118                                      \+    −      \+     C3     un    M          27 mo   Fever, Diarrhoea
  K135                                      \+    \+     −      ---    ---   ---        20 mo   Fever
  K136                                      \+    −      \+     A5     B2    P          23 mo   URTI
  K137                                      −     \+     \+     A3     un    un         6 mo    Fever
  K140                                      −     −      \+     C3     un    un         8 mo    Fever
  K141                                      −     \+     −      ---    ---   ---        19 mo   URTI, Diarrhoea
  K149                                      \+    −      \+     C3     un    un         30 mo   Fever, Diarrhoea
  K162                                      −     −      \+     C3     un    un         11 mo   Fever
  163                                       −     −      \+     un     B1    un         34 mo   Fever
  K164                                      −     −      \+     C3     un    un         14 mo   URTI
  K166                                      −     \+     −      ---    ---   ---        17 mo   URTI
  K180                                      −     \+     −      ---    ---   ---        9 mo    Fever
  K186                                      −     −      \+     C3     un    un         11 mo   Fever
  K190                                      −     \+     −      ---    ---   ---        21 mo   URTI and Rash
  K192                                      \+    \+     −      ---    ---   ---        18 mo   Fever and Rash
  K199                                      −     −      \+     C3     un    un         9 mo    Fever

un, KSHV DNA+,but undetectable by primers indicated; mo,months age;yr, year.

Patients positive for KSHV or HCMV are shown URTI, upper respiratory tract infection \[Fever with Rhinitis or Pharyngitis or tonsillitis\].

Clinical Features KSHV Infected Infants
---------------------------------------

The PCR reaction (1/50 of 0.2 ml blood with sensitivity of 10--100 copies) detected at least 2,500 copies/ml blood, consistent with KSHV viremia. Given the ages of the patients (6--34 months), these are most likely primary infections, with possible maternal or sibling transmission through non--sexual routes as suggested previously for this population and neighboring regions \[[@b11]; [@b20], [@b23]; [@b7]\]. Fever was the inclusion criteria and other hospital diagnosed causes of fever were excluded (malaria or bacterial infections). Amongst the 31 infants who were PCR positive for KSHV, upper respiratory tract infections were the most common symptom 45% (14/31), followed by diarrhea 19% (6/31), rash 3% (1/31) and rhinitis 3% (1/31) ([Table I](#tbl1){ref-type="table"}).

Nucleotide Sequencing and Genotype Analyses
-------------------------------------------

Many samples were at the limit of detection by PCR, which restricted subsequent multiple analyses by nucleotide sequencing. The PCR positive K1 loci was first examined by sequencing. The results showed the K1 A5 genotype, previously identified in infected children and in childhood KS in this region, but also unexpected diversity. The K1 A5 genotype was common 23% (5/22), now linked here with K12 B1 or B2 and K14.1 P genotypes, consistent with previous results for a distinct strain in this region ([Table I](#tbl1){ref-type="table"} and [Fig. 1](#fig01){ref-type="fig"}), and presenting with respiratory symptoms (4/5). However, also shown were K1--B (4/22), (prevalent in African adult KS) as well as K1--A2, A3, and C3, previously common in adult Mediterranean/Asian/Europe KS (C3, 7/22). There were HIV positive and negative examples of all. The Zambian infant blood KSHV sequences clustered with representative of K1 A, B, C, or D genotypes from adult KS biopsy samples ([Fig. 2](#fig02){ref-type="fig"}).

![Sequence analyses of K1 variable region, VRI loop, identifies genotype diversity in childhood KSHV from African endemic region. The K1 region was PCR amplified from blood DNA, sequenced and aligned against published representatives of K1 genotypes \[[@b38]\]. Dashes indicated identity.](jmv0079-1555-f1){#fig01}

![Phylogenetic tree of K1 sequences from childhood KSHV blood infections in comparison to reference genotypes from [Figure 1](#fig01){ref-type="fig"} shows extensive diversity. Scale and branch lengths indicate relative genetic distance. In the bootstrap analyses the multiple alignment was resampled generating 100 trees. Bootstrap values achieved are expressed in percentages and placed at the nodes.](jmv0079-1555-f2){#fig02}

At the loci from the right hand of the genome K12 and K14.1/K15 genotypes were identified, using primers to amplify regions as characterized previously \[[@b29]\]. Previous studies showed divergence of nucleotide sequences of K12 at selected positions, mostly intergenic non--coding, and some used as representative genotypes ([Fig. 3](#fig03){ref-type="fig"}). There were 21 Zambian infant K12 genotypes identified and these clustered with K12 B1 and B2 genotypes, similar to sequences identified in adult KS biopsies in other parts of Africa as shown \[[@b29]; [@b12]7rsqb; ([Fig. 3](#fig03){ref-type="fig"}). The PCR based assay for the K14.1/15 distinguishes by size the P or M genotypes. The dominance of the K14.1/15 P genotype (17/18) is in agreement with previous studies showing predominance in Eastern African regions also in adult KS biopisies ([Table I](#tbl1){ref-type="table"}) \[[@b16]\]. For all sites analyzed some samples could not be detected by the primers used, suggesting further diversity.

![Nucleotide changes in the K12 region shows B genotypes identified in African regions. Reference genotypes are shown (A, AC, M, B1, and B2), including Ugandan reference sequences from adultKS biopsy materials, compared to the Zambian infant patients blood genotypes showing B1 and B2. The K12 segment is in the reverse complement orientation (coding) from the genomic sequence. The positions of nucleotide variation and reference sequences are as shown previously with position 1 as in \[[@b29]; [@b12]\] or 118,065 in the BC1 genomic sequence, or position 51 in [@b29], (positions −22 is 30, and 64 is 115 in [@b29];). K12ORF, Kaposin A, ends at position 147 as in[@b29]\] and [@b12] or 117,919 in the BC1 genome \[[@b31]\]. The PCR product was from 118,116--117, 469. Hyphens and dots indicate identical or deleted residues.](jmv0079-1555-f3){#fig03}

One K1 sequence overlapped all of the genotypes, ABCD (K111), either a local progenitor virus or effects of recombination ([Figs. 1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}). This was distinct from previous progenitor strains (K1--43Berr closest, 18% divergence) \[[@b16]; [@b35]\]. However, the K12 B1 genotype from this sample was similar to other B1 sequences from the region.

DISCUSSION
==========

In earlier studies, of a childhood endemic KS region, Zambia, analyses of blood infection in five infants showed only K1--A5 genotypes and this correlated with the genotype identified in different infant and childhood KS samples \[[@b13]\]. Here the origin of the KSHV strains infecting infants is analyzed in a larger study of blood infections in 200 hospitalized febrile infants. KSHV sequences were identified in 31 individuals. Given the young age (6--34 months) of the patients, and the relative levels detected, these appeared to be primary or early infections of which little is known. In addition to fever, many had symptoms of upper respiratory tract infections or diarrhoea, but no evidence yet for KS. Multiple loci were used to genotype the virus. The results showed diverse adult--like genotypes identified in both HIV positive or negative infants. These included the following K1/K12/K14.1/15 genotypes: K1--A5, A2, A3, B, C3 or A/B/C/D; K12--B1 or B2; K14.1/15 P or M. It is also possible that given rapid increases in HIV/AIDS in Zambia, the genotype pool of KSHV may have expanded, leading to emergence of diverse childhood infections. Recently, blood DNA from five older children (\>5 years age) in Uganda also showed 3 K1--A5 and 2 K1--B \[[@b23]\]. This is consistent with results shown here, although here further loci have been analyzed, with more diversity identified in the Zambian region in a larger group of younger children and infants. Thus, in a childhood KS endemic region, childhood KSHV infection can occur with diverse genotypes.

Despite the diversity of genotypes identified in the infant blood KSHV infections, is there any evidence for distinct strains for childhood transmission? The K1A5 genotype is prevalent in KS biopsy samples from patients in regions of Africa where there is childhood endemic KS \[[@b13]; [@b16]; [@b12]\]. Furthermore, the P genotype of K14.1/15 is also linked to this region \[[@b16]\], where only one M genotype was identified. Moreover, only the K12 B genotype (both B1 and B2) was identified in these infant infections, and these genotypes are dominant in adult KS identified in other African regions \[[@b29]; [@b16]; [@b12]\]. Most of the K12 variation is in the 30 non--coding intergenic region. However, the encoded Kaposin A is a tumorigenic transforming gene interacting with cytohesin--1 integrin regulator, and two coding changes were identified ([Fig. 4](#fig04){ref-type="fig"}) \[[@b26]; [@b15]\]. One shown in some B1 genotypes,C64G gives rise to Leu34 to Val, though conservative, it disrupts an LXXLL motif (to LXXVL), reported required for cellular transformation \[[@b34]\]. The other substitution is divergent, G112C, giving Ala50 to Pro in all B genotypes compared to both referenceMand P type genomes (BC1 and GK18, respectively) \[[@b31]; [@b30]\]. Thus several genotype markers may link with childhood endemic KS endemic regions. However, the observation of multiple K1 genotypes and past evidence for linked genome diversity \[[@b29]\], suggests multiple KSHV strains can be transmitted to infants.

![Coding changes in the K12 Kaposin A gene. Zambian infant blood KSHV K12 B genotypes (from [Fig. 3](#fig03){ref-type="fig"}) compared to protein encoded by reference P type genome (GK18) \[[@b30]\]. A disrupted motif reported required for transformation is underlined \[[@b34]\].](jmv0079-1555-f4){#fig04}

Since the data shown here indicates there does not appear to be any strain restriction for infant infection in a region endemic for childhood KS, this implicates other cofactors for childhood KSHV transmission and KS development. Seroepidemiological studies on KSHV transmission, identify factors including genetic predisposition, low socioeconomic status, immunosuppresion from HIV/AIDS or other influences, plus surface water exposure, possibly linking to hygiene \[[@b8]; [@b20], [@b22]; [@b28]; [@b14]\]. In this regard, evidence for mother to child or close siblings transmission in African KS endemic populations has been demonstrated \[[@b11]; [@b20], [@b23]; [@b7]\] with virus detected in saliva and urine \[[@b2]; [@b3]; [@b21]\]. Factors for development of adult KS require KSHV seropositivity, and include linkage to higher socioeconomic status, water exposure, HIV/ AIDS immunosuppression, or immunogenetic regulation \[[@b36], [@b37]; [@b33]; [@b10]\]. However, not all African countries with high childhood KSHV seroprevalence have high childhood endemic KS, thus additional factors affect childhood endemic KS development. Whether these African childhood infections with diverse KSHV genotypes as shown here, have differences in subsequent KSHV transmission or KS development, remains to be determined and has important implications for vaccine design.
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